Pharming Group

Pharming Group Debt

The Debt of Pharming Group (PHARM.AS) as of Nov 19, 2026 is 115.79 M USD. In the previous year, Debt was 112.26 M USD — a change of 3.14% (higher).

Debt

115.79 MUSD

YoY

3.14%

Last updated:

In 2025, Pharming Group's total debt was 115.79 M USD, a 3.14% change from the 112.26 M USD total debt recorded in the previous year.

The Pharming Group Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
83.42 M USD
Jan 1, 2019
58.14 M USD
Jan 1, 2020
162.22 M USD
Jan 1, 2021
161.59 M USD
Jan 1, 2022
166.69 M USD
Jan 1, 2023
155.29 M USD
Jan 1, 2024
112.26 M USD
Jan 1, 2025
115.79 M USD
The Pharming Group Debt history
YEARDebtYoY
115.79 MUSD+3.14%
112.26 MUSD-27.71%
155.29 MUSD-6.84%
166.69 MUSD+3.16%
161.59 MUSD-0.38%
162.22 MUSD+179.03%
58.14 MUSD-30.31%
83.42 MUSD-14.47%
97.53 MUSD+37.61%
70.88 MUSD+308.63%
17.35 MUSD+796.55%
1.93 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pharming Group Stock analysis

What does Pharming Group do? Pharming Group NV was founded in 1988 and is headquartered in the Netherlands. The company specializes in the development and marketing of medical products for the treatment of rare diseases. Its business model is based on the discovery and development of recombinant proteins. These proteins are produced using genetic engineering techniques and serve as the foundation for the development of therapeutic products in various areas. The main focus of Pharming Group NV is the manufacturing and marketing of biopharmaceuticals. The company has a wide range of products used in the treatment of rare diseases, including C1-esterase inhibitor preparations used for acute attacks in hereditary angioedema. Another important product of Pharming Group NV is recombinant human lysozyme. It is used in the treatment of cystic fibrosis and has shown promising results as a therapeutic approach. Pharming Group NV also collaborates closely with various research and development organizations to develop new products and expand knowledge in the medical industry. The company has experienced impressive growth in recent years. In 2019, Pharming Group NV achieved a revenue of 149 million euros. A significant portion of this revenue was generated through the sale of C1-esterase inhibitor preparations. Pharming Group NV has also made a name for itself in the international market. The company has branches in the USA and Europe and works closely with international regulatory authorities to ensure smooth approval and marketing of its products. Overall, Pharming Group NV has a promising future as it continues to invest in research, development, and expansion of its product portfolio. By focusing on the development of products for the treatment of rare diseases, Pharming Group NV positions itself as a leading company in the medical industry and contributes to improving the lives of people worldwide. Pharming Group is one of the most popular companies on Eulerpool.

Debt Details

Understanding Pharming Group's Debt Structure

Pharming Group's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Pharming Group's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Pharming Group’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Pharming Group’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Pharming Group stock

Debt of Pharming Group is 115.79 M USD in 2025.

Debt of Pharming Group changed from 112.26 M USD to 115.79 M USD, representing a 3.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Pharming Group since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Pharming Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Pharming Group

All Key Metrics — Pharming Group